Sponsor Check › Person
Related person on Form D filings · address states as listed: CA, MA, WA, PA · listed Sep 16, 2010 → Nov 18, 2025
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 12:10 AM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 24, 2026, 12:10 AM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 12:10 AM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
0 of 19 offerings report sales commissions; 1 reports finder's fees totalling $1,950,345; 1 reports proceeds to related persons totalling $600,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Nov 18, 2025 D File 021-564321 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 4, 2021 D File 021-419730 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 21, 2021 D File 021-396659 | $0 | $0 | $0 The General Partner (or its designee) is entitled to the payment of a management fee payable by the Issuer. | None listed on this filing |
| EDGAR ↗ | Apr 7, 2021 D File 021-394949 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 5, 2021 D File 021-388545 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 18, 2019 D File 021-351428 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 13, 2019 D/A File 021-342330 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 30, 2019 D File 021-331749 | $0 | $0 | $0 The General Partner (or its designee) is entitled to the payment of a management fee payable by the Issuer. | None listed on this filing |
| EDGAR ↗ | Dec 31, 2018 D File 021-329222 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 19, 2018 D File 021-328368 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 29, 2018 D File 021-326810 | $0 | $0 | $0 | n/a no CRD number reported |
| EDGAR ↗ | Mar 16, 2018 D File 021-307907 | $0 | $0 | $0 | N/A no CRD number reported via N/A |
| EDGAR ↗ | Dec 18, 2017 D File 021-300967 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 31, 2017 D File 021-287745 | $0 | $0 | $600,000 (est.) Executive Salaries | None listed on this filing |
| EDGAR ↗ | Sep 12, 2016 D File 021-270454 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 30, 2014 D File 021-225481 | $0 | $1,950,345 | $0 | Leerink Partners LLC BrokerCheck CRD 39011 ↗ |
| EDGAR ↗ | Mar 26, 2014 D File 021-214271 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 20, 2012 D File 021-177000 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 16, 2010 D File 021-147844 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Dualitas Therapeutics, Inc. | Director | Nov 18, 2025 | D | $66,599,990 similar: $2,000,000–$19,999,994 | $32,599,997 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Platelet BioGenesis, Inc. | Director | Nov 4, 2021 | D | $35,416,789 similar: $500,000–$7,000,000 | $35,416,789 | 7 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Qiming U.S. Healthcare Fund III, L.P. group: Qiming | Director Managing Member of the General Partner | Apr 21, 2021 | D | $300,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Icosavax, Inc. | Director | Apr 7, 2021 | D | $99,729,701 similar: $2,000,000–$19,999,994 | $99,729,701 | 36 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | WindMIL Therapeutics, Inc. | Director | Feb 5, 2021 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $2,334,814 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Icosavax, Inc. | Director | Oct 18, 2019 | D | $51,007,373 similar: $2,000,000–$19,999,994 | $30,007,376 | 22 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Platelet BioGenesis, Inc. | Director | Aug 13, 2019 | D/A | $26,364,976 similar: $500,000–$7,000,000 | $26,364,976 | 34 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Platelet BioGenesis, Inc. | Director | Jun 19, 2019 | D | $11,364,976 similar: $500,000–$7,000,000 | $11,364,976 | 33 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Qiming U.S. Healthcare Fund II, L.P. group: Qiming | Director Managing Member of the General Partner | Jan 30, 2019 | D | $250,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Dermira, Inc. | Director | Dec 31, 2018 | D | $1,000,000 similar: $829,831–$9,999,998 | $1,000,000 | 1 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Amphivena Therapeutics, Inc. | Director | Dec 19, 2018 | D | $50,000,000 similar: $829,831–$9,999,998 | $38,694,170 | 15 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Aimmune Therapeutics, Inc. | Director | Nov 29, 2018 | D | $98,000,002 similar: $829,831–$9,999,998 | $98,000,002 | 1 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Aimmune Therapeutics, Inc. | Director | Mar 16, 2018 | D | $156,700,012 similar: $829,831–$9,999,998 | $156,700,012 | 2 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | Dermira, Inc. | Director | Dec 18, 2017 | D | $500,000 similar: $829,831–$9,999,998 | $500,000 | 1 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Platelet BioGenesis, Inc. | Director | May 31, 2017 | D | $10,000,000 similar: $2,000,000–$19,999,994 | $10,000,000 | 32 similar: 2–16 | $10,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Dermira, Inc. | Director | Sep 12, 2016 | D | $1,500,000 similar: $829,831–$9,999,998 | $1,500,000 | 1 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Dermira, Inc. | Director | Sep 30, 2014 | D | $50,999,996 similar: $829,831–$9,999,998 | $50,999,991 | 15 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | FIVE PRIME THERAPEUTICS INC | Director | Mar 26, 2014 | D | $21,040,488 similar: $2,000,000–$19,999,994 | $21,040,488 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | FIVE PRIME THERAPEUTICS INC | Director | Apr 20, 2012 | D | $10,000,000 | $10,000,000 | 1 | No minimum reported |
| EDGAR ↗ | FIVE PRIME THERAPEUTICS INC | Director | Sep 16, 2010 | D | $7,499,999 | $7,499,999 | 1 | No minimum reported |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); Other / 506(b) (18,678 filings); Pooled Investment Fund / 506(b) (83,801 filings); Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Separate person records under the same name, not combined with this page. Each line says whether it is listed on an issuer this record is also listed on (a second identifier); where it is not, it could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Mark McDade. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Mark McDade appears on a new Form D, or when a court case or SEC action is matched to them. See plans →